Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients GlobeNewswire - Thu Dec 18, 3:35PM CST

Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis...

ANVS : 3.66 (+2.23%)
Annovis to Host Corporate Update Webinar on January 28, 2026 GlobeNewswire - Tue Dec 16, 7:00AM CST

MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 3.66 (+2.23%)
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group GlobeNewswire - Wed Dec 3, 7:00AM CST

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 3.66 (+2.23%)
Annovis Announces Two Presentations at the CTAD 2025 Conference GlobeNewswire - Mon Nov 24, 7:00AM CST

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 3.66 (+2.23%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 FinancialNewsMedia - Tue Nov 18, 7:45AM CST

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

AVAI : 0.3216 (-1.23%)
ANVS : 3.66 (+2.23%)
RXRX : 4.40 (+0.92%)
ZYME : 26.86 (+0.26%)
NTLA : 9.59 (+1.80%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 GlobeNewswire - Tue Nov 18, 7:45AM CST

MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...

AVAI : 0.3216 (-1.23%)
ANVS : 3.66 (+2.23%)
RXRX : 4.40 (+0.92%)
ZYME : 26.86 (+0.26%)
NTLA : 9.59 (+1.80%)
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study GlobeNewswire - Tue Nov 18, 7:00AM CST

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 3.66 (+2.23%)
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients GlobeNewswire - Mon Nov 17, 7:00AM CST

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions...

ANVS : 3.66 (+2.23%)
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results GlobeNewswire - Wed Nov 12, 7:00AM CST

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative...

ANVS : 3.66 (+2.23%)
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program GlobeNewswire - Thu Nov 6, 7:00AM CST

All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached the 6-month treatment milestone The study is now 25% complete,...

ANVS : 3.66 (+2.23%)

Barchart Exclusives

AI Bubble Fears Scaring You Off? Buy This Magnificent 7 Stock for Stability. Barchart - 10 minutes ago
Apple has long been seen as an AI laggard. However, the stock could fit into portfolios of investors worried about an AI bubble. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot